IP Library Granted Patent US 7,060,695
Granted Patent B2
US 7,060,695 · App. 10/072,215 · Granted Jun 13, 2006

Method to prevent vision loss

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,060,695
App. No.
10/072,215
Granted
Jun 13, 2006
Kind
B2
Abstract

An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.

Claims (25)

1. A method of improving photodynamic therapy (PDT) mediated treatment of choroidal neovasculature in a subject comprising

providing, during a period of about three months following an initial PDT treatment, at least two additional PDT treatments to said subject after evaluations for neovascular leakage at about 45 days and about 90 days following said initial PDT treatment.

2. A method of improving photodynamic therapy (PDT) mediated treatment of choroidal neovasculature in a subject comprising

providing, during a period of about three months following an initial PDT treatment, a total of at least three additional PDT treatments following said initial PDT treatment.

3. The method of claim 2 wherein a total of three additional PDT treatments are provided at about 30 days, at about 60 days and at about 90 days following said initial PDT treatment.

4. The method of claim 2 wherein a total of at least three additional PDT treatments are provided at about 15 days, at about 30 days, at about 45 days, at about 60 days, at about 75 days and at about 90 days following said initial PDT treatment.

5. A method of improving photodynamic therapy (PDT) mediated treatment of choroidal neovasculature in a subject comprising providing, during a period of about six months following an initial PDT treatment, additional PDT treatments to said subject after evaluations for neovascular leakage at intervals of about 60 days.

6. The method of claim 1 , 2 , or 5 , wherein the CNV is in a subject afflicted or diagnosed with age-related macular degeneration (AMD).

7. The method of claim 6 , wherein the AMD is the “wet” form.

8. The method of claim 1 , 2 , or 5 , wherein said additional PDT treatments comprise the administration of a photosensitizer (PS).

9. The method of claim 8 , wherein the PS is administered at a concentration ranging between about 2 to 8 mg PS per square meter of body surface area of said subject.

10. The method of claim 9 , wherein the PS is administered at a concentration of 6 mg PS per square meter of body surface are of said subject.

11. The method of claim 8 , wherein the PS is a green porphyrin.

12. The method of claim 11 , wherein the green porphyrin is selected from a group consisting of BPD-DA, BPD-DB, BPD-MA, BPD-MB, EA6, and B3.

13. The method of claim 12 , wherein the green porphyrin is BPD-MA.

14. The method of claim 11 , wherein the PS is coupled to a specific binding ligand.

15. The method of claim 8 , wherein the PS is formulated with a carrier.

16. The method of claim 15 , wherein the formulation is selected from the group consisting of a liposome, emulsion, or aqueous solution.

17. The method of claim 1 , 2 , or 5 , wherein said additional PDT treatments comprise irradiation with electromagnetic radiation containing wavelengths in the visible light spectra.

18. The method of claim 17 , wherein the irradiation provides between 12.5 J/cm 2 and 100 J/cm 2 .

19. The method of claim 17 , wherein said irradiating occurs between 5 to 30 minutes after administration of a photosensitizer.

20. A method of improving photodynamic therapy (PDT) mediated treatment of choroidal neovasculature in a subject comprising providing, during a period of about six months following an initial PDT treatment, a total of at least three additional PDT treatments following said initial PDT treatment to said subject after evaluation for neovascular leakage.

21. The method of claim 20 , wherein the total of three additional treatments are provided at about 45 days, at about 90 days, and at about 135 days following said initial PDT treatment.

22. The method of claim 20 , further comprising providing, during a period of about six months following the initial PDT treatment, a total of five additional PDT treatments following said initial PDT treatment to said subject after evaluations for neovascular leakage.

23. The method of claim 22 , wherein the total of five additional treatments are provided at about 30 days, at about 60 days, at about 90 days, at about 120 days, and at about 150 days following said initial PDT treatment.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
CHANGE OF NAME Recorded Jan 13, 2023
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: BAUSCH HEALTH COMPANIES INC.
Reel/Frame 062389/0306 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →